U.S. Markets closed

Teva Pharmaceutical Industries Limited (TEVA)

New York Stock Exchange Consolidated Issue - New York Stock Exchange Consolidated Issue Delayed Price. Currency in USD
Add to watchlist
17.01-0.03 (-0.18%)
At close: 4:00PM EDT

17.05 +0.04 (0.24%)
After hours: 7:35PM EDT

People also watch
MYLGILDNVSAMGNBMY
Full screen
Previous Close17.04
Open16.94
Bid17.03 x 400
Ask17.05 x 5700
Day's Range16.73 - 17.47
52 Week Range16.73 - 53.96
Volume14,915,549
Avg. Volume14,934,885
Market Cap17.27B
Beta0.51
PE Ratio (TTM)218.08
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.10 (6.48%)
Ex-Dividend Date2017-06-01
1y Target EstN/A
Trade prices are not sourced from all markets
  • Teva Women's Health Unit Attracts Interest of Church & Dwight, Cooper
    Bloomberg12 hours ago

    Teva Women's Health Unit Attracts Interest of Church & Dwight, Cooper

    Teva Pharmaceutical Industries Ltd.’s women’s health unit is drawing interest from Church & Dwight Co. and Cooper Cos., people familiar with the matter said, as the troubled Israeli drugmaker sells assets ...

  • Barrons.comyesterday

    UPDATE: Shire: There Goes the CFO!

    Update: I spoke with Shire (SHPG) CFO Jeff Poulton about his decision to leave, and he was quick to dispel any concerns that his departure was about anything except his desire to pursue a new opportunity. Poulton also said that calling Shire a specialty-pharmaceutical company is a misnomer, as an overwhelming percentage of revenue now comes from its orphan drug business, a point raised by analyst Evercore ISI analyst Josh Schimmer, who wrote that Shire has "biotech cash flows with a spec pharma valuation" in a note last week. Shares of Shire have fallen 4% to $139.71 at 1:26 p.m. today.

  • TheStreet.comyesterday

    Teva Must Clear Three Big Hurdles to Reclaim Its Perch

    Analysts are most critical about Teva's plan to cut $5 billion in debt by the end of the year.